《Journal Of Oncology Pharmacy Practice》雜志的最新年發文量為239篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在腫瘤學領域的學術影響力。
該刊聚焦于醫學-腫瘤學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 。
Journal Of Oncology Pharmacy Practice 雜志發文統計
文章名稱引用次數
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade54
- Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation13
- Demonstrating the value of the oncology pharmacist within the healthcare team12
- Pembrolizumab-induced myasthenia gravis: A fatal case report11
- Adherence to oral chemotherapy: Challenges and opportunities11
- Updates and novel treatments in urothelial carcinoma9
- Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen8
- Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events8
- Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors7
- Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma7
國家/地區發文量
- USA446
- Turkey108
- Canada85
- France30
- Spain30
- Japan28
- Australia24
- England23
- Italy23
- Saudi Arabia17
